隐源性肝硬化诊治的临床思维

详细信息    查看全文 | 推荐本文 |

英文篇名：The clinical thinking of diagnosis and treatment of cryptogenic cirrhosis 作者：尹昕茹 ; 陈东风 英文作者：YIN Xin-ru;CHEN Dong-feng;Department of Gastroenterology,Amy Medical Center of PLA (Daping Hospital); 关键词：肝硬化 ; 隐源性肝硬化 ; 肝窦阻塞综合征 ; 肝豆状核变性 英文关键词：cirrhosis;;cryptogenic cirrhosis;;hepatic sinusoidal obstruction syndrome;;hepatolenticular degeneration 中文刊名：JLYB 英文刊名：Journal of Medical Postgraduates 机构：陆军军医大学陆军特色医学中心大坪医院消化内科; 出版日期：2019-06-15 出版单位：医学研究生学报 年：2019 期：v.32;No.266 语种：中文; 页：JLYB201906005 页数：4 CN：06 ISSN：32-1574/R 分类号：22-25

摘要

隐源性肝硬化(CC)即不明原因的肝硬化,临床较为常见。随着诊治水平的提高及诊治手段的多样化,CC的发病率呈逐渐下降趋势。在其诊治过程中,完善的临床思维可有助于临床医师对现有临床资料进行分析、评价,有望进一步提高隐源性肝硬化病因诊断率。文中从疾病谱思维法、解剖学思维法以及宏观微观思维法等方面对于CC诊治的临床思维进行阐述。
        Cryptogenic cirrhosis(CC),cirrhosis of unknown cause,is common in clinic. With the improvement of the level of diagnosis and the diversification of the diagnosis and treatment,the incidence of CC is gradually declining. In the process of diagnosis and treatment,perfect clinical thinking can help clinicians to analyze and evaluate the existing clinical data,and it is expected to further improve the diagnostic rate of CC. In this paper,the clinical thinking of CC diagnosis and treatment is expounded from the aspects of disease spectrum thinking,anatomy thinking and macroscopic micro thinking.

引文

[1]Gines P,Quintero E,Arroyo V,et al.Compensated cirrhosis:natural history and prognostic factors[J].Hepatology,1987,7(1):122-128.
    [2]Baki JA,Tapper EB.Contemporary Epidemiology of Cirrhosis[J].Curr Treat Options Gastroenterol,2019,17(2):244-253.
    [3]Kang JH,Matsui T.Changing Etiology in Liver Cirrhosis in Sapporo,Japan[J].Euroasian J Hepatogastroenterol,2018,8(1):77-80.
    [4]Thuluvath PJ,Kantsevoy S,Thuluvath AJ,et al.Is cryptogenic cirrhosis different from NASH cirrhosis?[J]J Hepatol,2018,68(3):519-525.
    [5]Xiong J,Wang J,Huang J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China:a ten-year retrospective study[J].Clinics(Sao Paulo),2015,70(8):563-568.
    [6]Xu L.,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917.
    [7]尹昕茹,陈东风,文良志,重视非酒精性脂肪性肝硬化的临床诊断和治疗[J].重庆医学,2018,47(21):2765-2767.
    [8]郭严,张世荣,文良志,等.我国吡咯烷生物碱致肝窦阻塞综合征的临床特征分析[J].临床肝胆病杂志,2018,34(6):1277-1281.
    [9]中华医学会消化病分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京)[J].临床肝胆病杂志,2017,33(9):1627-1637.
    [10]Compston A.Progressive lenticular degeneration:a familial nervous disease associated with cirrhosis of the liver[J].Brain,2009,132(Pt 8):1997-2001.
    [11]Rodriguez-Castro KI,Hevia-Urrutia F.J,Sturniolo GC.Wilson's disease:A review of what we have learned[J].World J Hepatol,2015,7(29):2859-2870.
    [12]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Wilson's disease[J].J Hepatol,2012,56(3):671-685.
    [13]Hedera P.Update on the clinical management of Wilson's disease[J].Appl Clin Genet,2017,10:9-19.
    [14]Xie,JJ,Wu ZY.Wilson's Disease in China[J].Neurosci Bull,2017,33(3):323-330.